Mumbai, May 16 -- Rivaroxaban is a prescription medication used in the treatment of deep vein thrombosis and pulmonary embolism, to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation.

"The approval will further strengthen Biocon's portfolio of vertically integrated drug products," the company said in a statement.

Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets.

The company'...